Results 231 to 240 of about 13,632,376 (348)

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Comparison of medical history documentation efficiency and quality based on GPT-4o: a study on the comparison between residents and artificial intelligence. [PDF]

Front Med (Lausanne)
Lu X, Gao X, Wang X, Gong Z, Cheng J, Hu W, Wu S, Wang R, Li X.   +8 more
europepmc   +1 more source

The History of Medical Education in Europe and the United States, With Respect to Time and Proficiency

Academic medicine : journal of the Association of American Medical Colleges, 2018
E. Custers, O. Cate
semanticscholar   +1 more source

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

Molecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor, Julio Celis, Ulrik Ringborg   +2 more
wiley   +1 more source

Machine Learning-Based Dizziness/Vertigo Disease Diagnosis by Combining Medical History and Signs. [PDF]

J Otolaryngol Head Neck Surg
Zhao Y, Tian X, Wu H, Xu M, Yang R, Xiao J, Zhu Z.   +6 more
europepmc   +1 more source

Role of medical history and medication use in the aetiology of upper aerodigestive tract cancers in Europe: the ARCAGE study.

Annals of Oncology, 2012
Tatiana V. Macfarlane, Gary J. Macfarlane, N. Thakker, S. Benhamou, Christine Bouchardy, Wolfgang Ahrens, H. Pohlabeln, P. Lagiou, A. Lagiou, A. Lagiou, X. Castellsagué, A. Agudo, A. Slámová, Jan Plzák, Franco Merletti, L. Richiardi, Renato Talamini, L. Barzan, K. Kjaerheim, Cristina Canova, Lorenzo Simonato, David I. Conway, P. McKinney, P. Thomson, Philip Sloan, A. Znaor, Claire M. Healy, B. McCartan, M. Marron, P. Brennan   +29 more
semanticscholar   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Pioneering Physician: Dr. Elizabeth Blackwell and the Path to Medical History. [PDF]

Cureus
Thakur J, Choudhari SG, Gaidhane A.
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source